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Abstract
Background: Antibody Directed Enzyme Prodrug Therapy (ADEPT) can be used to generate cytotoxic
agents at the tumor site. To date non-human enzymes have mainly been utilized in ADEPT. However,
these non-human enzymes are immunogenic limiting the number of times that ADEPT can be
administered. To overcome the problem of immunogenicity, a fully human enzyme, capable of converting
a non-toxic prodrug to cytotoxic drug was developed and joined to a human tumor specific scFv yielding
a fully human targeting agent.
Methods: A double mutant of human purine nucleoside phosphorylase (hDM) was developed which
unlike the human enzyme can cleave adenosine-based prodrugs. For tumor-specific targeting, hDM was
fused to the human anti-HER2/neu single chain Fv (scFv), C6 MH3B1. Enzymatic activity of hDM with its
natural substrates and prodrugs was determined using spectrophotomeric approaches. A cell proliferation
assay was used to assess the cytotoxicity generated following conversion of prodrug to drug as a result of
enzymatic activity of hDM. Affinity of the targeting scFv, C6 MH3B1 fused to hDM to Her2/neu was
confirmed using affinity chromatography, surface plasmon resonance, and flow-cytometry.
Results: In vitro hDM-C6 MH3B1 binds specifically to HER2/neu expressing tumor cells and localizes hDM
to tumor cells, where the enzymatic activity of hDM-C6 MH3B1, but not the wild type enzyme, results in
phosphorolysis of the prodrug, 2-fluoro-2'-deoxyadenosine to the cytotoxic drug 2-fluoroadenine (F-Ade)
causing inhibition of tumor cell proliferation. Significantly, the toxic small drug diffuses through the cell
membrane of HER2/neu expressing cells as well as cells that lack the expression of HER2/neu, causing a
bystander effect. F-Ade is toxic to cells irrespective of their growth rate; therefore, both the slowly
dividing tumor cells and the non-dividing neighboring stromal cells that support tumor growth should be
killed. Analysis of potential novel MHCII binding peptides resulting from fusion of hDM to C6 MH3B1 and
the two mutations in hDM, and of the structure of hDM compared to the wild-type enzyme suggests that
hDM-C6 MH3B1 should exhibit minimal immunogenicity in humans.
Conclusion: hDM-C6 MH3B1 constitutes a novel human based protein that addresses some of the
limitations of ADEPT that currently preclude its successful use in the clinic.
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Specific delivery of therapeutic drugs to tumor cells has
been a major focus of cancer therapy. One approach to
specific drug delivery has been the use of Antibody
Dependent Enzyme Prodrug Therapy (ADEPT) in which
an enzyme is joined to a tumor specific antibody which
localizes the enzyme in the vicinity of the tumor. A rela-
tively non-toxic prodrug, which is a substrate for the
enzyme, is then administered and converted to a cytotoxic
drug at the tumor site where the enzyme is localized,
resulting in tumor cell death [1-4]. For ADEPT to be effec-
tive, the prodrug must be cleaved to a cytotoxic agent only
by the administered enzyme [4]. Therefore, endogenously
expressed human enzymes cannot be utilized for ADEPT,
since the prodrug will be converted to a cytotoxic drug not
only in the vicinity of tumor, but also at sites where
endogenous enzyme is expressed causing systemic toxic-
ity. On the other hand, if a non-human enzyme is used, it
will be immunogenic, preventing multiple administra-
tions [2].
One strategy for achieving effective ADEPT is to change
the substrate specificity of a human enzyme such that it
can cleave prodrugs that are not substrates of wild type
enzyme. Recently, we have reported a mutated human
purine nucleoside phosphorylase that is capable of utiliz-
ing adenosine-based prodrugs as substrate [5]. The endog-
enously expressed human purine nucleoside
phosphorylase (hPNP) cleaves 6-oxo purines to their cor-
responding free base and ribose-1-phosphate, but does
not use adenosine or adenosine-based prodrugs [5,6].
However, following two mutations
(Glu201Gln:Asn243Asp) in the purine binding pocket of
hPNP the resulting enzyme (hDM) effectively cleaves ade-
nosine-based prodrugs including 2-fluoro-2'-deoxyade-
nosine (F-dAdo), Cladribine, and 2-fluoroadenosine to
their corresponding cytotoxic base [5]. When the activity
of hDM was tested in vitro, generation of the toxic metab-
olite 2-fluoroadenine (F-Ade) due to phosphorolysis of F-
dAdo resulted in inhibition of cell proliferation and apop-
tosis of tumor cells [5]. Therefore, hDM-F-dAdo consti-
tutes an attractive enzyme-prodrug combination for use in
ADEPT.
We now report the further development of hDM for use in
ADEPT. To localize hDM to tumors, it was fused at its C-
terminus to an anti-HER2/neu single chain Fv (scFv), C6
MH3B1 via a rigid α-helical linker. C6 MH3B1 is the result
of affinity maturation of the scFv C6.5 isolated from a
fully human non-immune phage library [7] and exhibits
high specificity, affinity, and most importantly a slow dis-
sociation rate from the tumor associated antigen, HER2/
neu [7]. The fusion protein, hDM-C6 MH3B1 forms an
active trimer capable of cleaving F-dAdo to F-Ade in a
dose-dependent manner with kinetic parameters compa-
rable to those previously reported [5]. In vitro hDM-C6
MH3B1 localizes to tumor cells and its cleavage of F-dAdo
results in tumor cell death. The F-Ade generated will also
inhibit the proliferation of neighboring tumor cells that
lack expression of the tumor antigen, the so called
"bystander effect". Moreover, we showed that F-Ade is as
toxic to slowly growing and non-proliferating cells as it is
to rapidly dividing tumor cells. The binding affinity of
hDM-C6 MH3B1 for HER2/neu was found to be similar to
that of the single chain C6 MH3B1, with hDM-C6 MH3B1
binding both soluble and cell surface expressed HER2/
neu. hDM-C6 MH3B1 is relatively stable in the presence of
serum at 37°C. Comparison of the structures of hDM and
the wild type enzyme as well as analysis of potential
MHCII binding peptides generated as a result of fusion of
two proteins and the Glu201Gln:Asn243Asp mutations
suggest that hDM-αH-C6.5 MH3B1 should have minimal
immunogenicity in humans. Therefore, the hDM-C6
MH3B1-F-dAdo combination addresses many of the cur-
rent limitations of ADEPT and provides an excellent can-
didate for treatment of HER2/neu expressing tumors with
minimum systemic toxicity or immunogenicity.
Methods
Materials
Guanosine and F-Ade were purchased from Sigma-Aldrich
(St. Louis, MO), and F-dAdo was purchased from Berry &
Associates (Dexter, MI). CT26 was purchased from ATCC
(Manassas, VA). Construction and characterization of
CT26HER2/neu is described previously [8]. MCF7-HER2
[9] was a gift from Dr. Dennis Slamon (University of Cal-
ifornia, Los-Angeles). Cells were cultured in Iscove's Mod-
ified Dulbecco's Medium (IMDM; GIBCO, Carlsbad, CA)
containing 5% calf-serum (GIBCO) for CT26 and
CT26HER2/neu and IMDM containing 10% fetal bovine
serum (GIBCO), 1% non-essential amino acids (GIBCO)
and 1% sodium pyruvate (GIBCO) for MCF-7HER2 cells.
The expression vector for production of ECDHER2 was a gift
from Dr. James Marks (University of California, San-Fran-
cisco).
Plasmid construction and protein purification
Cloning of hPNP and hDM with αH linker at its C-termi-
nus was described previously [5]. To construct hPNP-αH-
C6.5 MH3B1 or hDM-αH-C6.5 MH3B1 genes, first PNP-
αH was amplified using 5'gcggccgcgataccaccgatatccaccatg
gagacagacacactcctgctatgggtactgctgctctgggttccaggttccactgga-
gacgagaatggatac acctatgaagattataagaac3' and 5'taaaga
ggccgcagccaaagcgca ggtgcagctggtgcagtctgg3' as forward
and reverse primers respectively. The forward primer con-
tains a NotI site, Kozak sequence and signal peptide, and
the beginning of the PNP gene. The reverse primer
encodes the αH linker and the beginning of C6.5 MH3B1.
The sequence for the signal peptide is gatatccaccatgga
gacagacacactcctgctatgg gtactgctgctctgggttccaggttccactgga-Page 2 of 12
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AEAAAKEAAAKA. The C6 MH3-B1 gene was PCR ampli-
fied with the forward primer complementary to the
reverse primer used for PNP amplification encoding for
αH linker, and the beginning of the C6.5 MH3B1
sequence. 5'ggagggaccaaggt caccgtcctaggtcgttaata
atctaga3', which encodes the C-terminus of scFv and an
XbaI site, was used for the reverse primer. The PCR prod-
uct of each gene was purified, annealed and used as tem-
plate for the final PCR amplification using PNP forward
primer containing a NotI site and C6.5 MH3B1 reverse
primer containing a XbaI site. The PCR product was
cloned into the TOPO-Blunt vector (Invitrogen, Carlsbad,
CA) and the sequence confirmed. The final product
encoding the Kozak sequence, signal sequence, hPNP or
hDM followed by an αH linker and C6.5 MH3B1 was
cloned into the Novagen vector pcDNA3.1 (+) using NotI
and XbaI sites.
Expression, purification and SDS PAGE
The pcDNA3.1 (+) vector containing the insert was tran-
siently transfected into 293T cells using CalPhos Mamma-
lian Transfection Kit (Clonetech Laboratories, Inc.
Mountain View, CA) according to manufacturer's recom-
mendation. Culture supernatant was collected three and
six days post transfection and passed through an affinity
column that consisted of ECDHER2 conjugated to CNBr
activated Sepharose beads according to manufacturer's
recommendation. The affinity column was washed with
30 column volumes of PBS, and 3 column volumes of ace-
tic acid pH 4.5. The bound protein was eluted with 0.1 M
glycine pH 2.5 and immediately neutralized with Tris/
HCl pH 8.0. Protein concentration was determined by
absorbance at 280 nm using E0.1% = 1.6 with molecular
mass of 60,392 Da, and the protein purity was assessed
using Coomassie blue-stained SDS polyacrylamide gel.
Expression and purification of ECDHER2 is described previ-
ously [8].
Size exclusion analysis of hDM-αH-C6.5 MH3B1
To determine whether hDM-αH-C6.5 MH3B1 exists as
monomers and/or as polymers, 100 μg of purified protein
was analyzed by gel filtration on a Superose 6 HR 10/30
column (GE Healthcare, Anaheim, CA) by HPLC in PBS at
0.2 ml/min. BIORAD gel filtration standards (catalog #
151-1901; Hercules, CA) composed of Thyroglobulin
(670,000 Da), γ-globulin (158,000 Da), Ovalbumin
(44,000 Da), Myoglobin (17,000 Da), and Vitamin B12
(1,350 Da) were used as molecular weight standards.
Enzyme activity and kinetic parameters of PNP 
fusionproteins
The method for determining the enzymatic activity of
hPNP or any of its mutant constructs was previously
described in detail [5]. Briefly, enzymatic cleavage of F-
dAdo to F-Ade by PNP was followed by a decrease in
absorbance at 260 nm and a concurrent increase in
absorbance at 280 nm with a molar extinction coefficient
of 16,300 M-1cm-1 at 260 nm and 1,300 M-1cm-1 at 280
nm. Phosphorolysis of guanosine to guanine was fol-
lowed by the decrease in absorbance at 257 nm using a
molar extinction coefficient of 13,700 M-1cm-1 for guano-
sine.
Association of hDM-αH-C6.5 MH3B1 with HER2/neu 
expressingcells
CT26, CT26-HER2/neu, and MCF-7HER2 cells were
seeded at 5 × 103 cells in 50 μl per well in a 96-well micro-
titer plate. CT26 and CT26-HER2/neu were grown in the
presence of Iscove's Modified Dulbecco's Medium
(GIBCO; Carlsbad, CA) containing 5% calf-serum
(GIBCO). MCF-7HER2 cells were grown in the presence
of ISCOVE's Modified Dulbecco's Medium containing
10% Fetal Bovine Serum (GIBCO), 1% Non-essential
amino acids (GIBCO), and 1% Sodium Pyruvate
(GIBCO). The next day 50 μl of increasing concentrations
of hDM-αH-C6.5 MH3B1 were added in triplicate to cells
and incubated for 45 minutes at room temperature. The
unbound proteins were carefully pipetted out, and each
well was gently washed twice with 200 μl of cold medium.
This was followed by addition of 100 μl of growth
medium containing F-dAdo at a final concentration of 1.5
μM for CT26 or CT26-HER2/neu cells or 6 μM for MCF-
7HER2 cells [5]. After 72 hours incubation at 37°C, inhi-
bition of cell growth was determined by an MTS assay
according to manufacturer's recommendation. When the
fusion proteins were directly added, cells were seeded as
described above. Then 40 μl of fusion protein at different
dilutions and 10 μl of F-dAdo stock (1.5 μM for CT26 or
CT26HER2/neu cells and 6 μM for MCF-7HER2 cells)
were added to cells and incubated for 72 hours at which
time the degree of cell proliferation was determined by
MTS assay. To examine the bystander effect of the fusion
protein, mixtures of CT26 and CT26HER2/neu cells were
seeded overnight at 5 × 103 cells per well at different
ratios, and the assay was completed as described above
with hDM-αH-C6.5 MH3B1 and F-dAdo at final concen-
trations of 0.1 μM and 1.5 μM, respectively.
Cytotoxicity of F-Ade to cells with different growth rates
MCF7-HER2 cells were seeded overnight at a density of 5
× 103 in the presence of 10% fetal bovine serum. The fol-
lowing day, cells were washed carefully, the medium
replaced with serum at different levels to influence growth
rate, and cells grown for an additional 72 hours in the
presence or absence of 6 μM F-Ade. The level of cell viabil-
ity or the number of cells were determined by MTS assay,
or by visually counting them.Page 3 of 12
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To evaluate the stability of hDM-αH-C6.5 MH3B1, hDM-
αH-C6.5 MH3B1 at a concentration of 0.001 μM was
incubated in the presence of fetal bovine serum at 37°C
for up to 23 hours. Samples were removed at different
times and stored at 4°C. After the last sample was
removed, each was added to overnight seeded MCF-
7HER2 cells (5 × 103/well) in the presence of 6 μM F-
dAdo, and the activity of hDM-αH-C6.5 MH3B1 was
determined by its ability to convert F-dAdo to F-Ade and
inhibit cell proliferation as assessed by MTS assay 72
hours after addition of fusion protein and prodrug to
cells.
SPR analysis of interaction of ECDHER2 with hDM-αH-C6.5 
MH3B1
inding of hDM-αH-C6.5 MH3B1 to ECDHER2 was evalu-
ated using surface plasmon resonance (SPR) on a BIAcore
T-100. To determine the affinity of the monomeric inter-
action of hDM-αH-C6.5 MH3B1 with ECDHER2, 533 reso-
nance units (RU) of trimeric hDM-αH-C6.5 MH3B1 were
immobilized on the surface of a CM5 sensor chip follow-
ing the standard amine coupling procedure according to
the manufacturer's suggestion. The remaining active
groups were blocked by ethanolamine. A control surface
was generated by following the same procedure, but with-
out addition of protein. ECDHER2 at concentrations rang-
ing from 10 to 100 nM in PBS was flowed over the surface
at 30 μl/min for 750 second. This was followed by a 45
minute dissociation phase at the same flow rate. The sur-
face was regenerated by two injections of glycine at pH 9.5
for 20 seconds. As control, PBS alone or a mixture of 100
nM ECDHER2 and 1 μM hDM-αH-C6.5 MH3B1 incubated
at 25°C for 30 minutes was injected on the surface. Bind-
ing of ECDHER2 to immobilized hDM-αH-C6.5 MH3B1
was monitored in real time by following the association
and dissociation phases on the experimental surface with
control surface subtracted. Binding parameters were deter-
mined using the 1:1 binding model by BIAevalution 3.0
software.
Flow cytometry analysis of hDM-αH-C6.5 MH3B1 binding 
to HER2/neu expressing cells
CT26, CT26HER2/neu or MCF-7HER2 cells (5 × 105 cells/
sample) were incubated with either biotinylated or Alexa-
fluor labeled hDM-αH-C6.5 MH3B1 for 30 minutes on
ice and then washed twice with FACS buffer [PBS pH 6.8
with 1% calf-serum]. If biotinylated hDM-αH-C6.5
MH3B1 was used, cells were then stained for thirty min-
utes with PE-labeled streptavidin at final concentration of
0.3 μg/ml (BD Bioscience; Franklin Lakes, NJ), and
washed twice. Fluorescence was measured on a cytofluor-
ometer (FACSCalibur; BD Bioscience) and the mean fluo-
rescence was analyzed using the Flowjo software (Treestar,
Ashland, OR). Biotin (catalog number: 21336; PIERCE;
Rockford, IL) or Alexa-fluor (catalog number: A10235;
Invitrogen) conjugation of hDM-αH-C6.5 MH3B1 was
carried out according to the manufacturer's recommenda-
tion.
Results
Construction and purification of hDM-αH-C6.5 MH3B1
We have previously shown that hPNP with the two muta-
tions Glu201Gln:Asn243Asp, unlike wild-type hPNP,
converts a relatively non-toxic prodrug, F-dAdo to the
cytotoxic drug F-Ade [5]. With the goal of being able to
target hDM to the tumor site, we fused it at its C-terminus
to a human anti-HER2/neu single chain Fv (C6.5 MH3-
B1) [7] through a rigid α-helical linker [10,11] (Fig. 1A).
C6.5 MH3B1 has been reported to bind to HER2/neu with
high affinity and specificity [7]. The available crystal struc-
ture of hPNP [12-14] suggested that fusing C6.5 MH3B1
to the C-terminus of the enzyme would have minimal
affect on its enzymatic activity, since the C-terminus is dis-
tal from the enzyme active site. The rigid α-helical linker
[11,12], instead of a flexible GlySer linker was used to
restrict the flexibility of the fusion protein. The plasmid
encoding the hDM-αH-C6 MH3B1 was transiently
expressed in 293T cells, the supernatant harvested and the
protein purified by passage through an affinity column
composed of ECDHER2 conjugated to Sepharose beads.
The eluted protein was 99% pure as judged by Coomasie
blue staining with 300 μg of protein obtained from 150
ml of culture supernatant (Fig. 1B). Analysis of the protein
by size exclusion chromatography indicated that the
fusion protein mainly existed as a 180 kDa homotrimer
(Fig. 1C) of 60 kDa subunits.
hDM-αH-C6.5 MH3B1 unlike hPNP-αH-C6.5 MH3B1 
converts the non-toxic prodrug F-dAdo to the cytotoxic 
drug, F-Ade
The activity of hDM-αH-C6 MH3B1 was examined in a
spectrophotometeric assay in which conversion of F-dAdo
to F-Ade was followed by a decrease in absorbance at 260
nm and a concurrent increase in absorbance at 280 nm.
The fusion protein had a KM of 264 μM and a kcat of 0.155
s-1 with an overall efficiency of 586 M-1s-1 (Fig. 2A, Table
1). When compared to the enzymatic activity of hDM
fused to a short anti-HER2/neu peptide called AHNP
[5,15], hDM-αH-C6.5 MH3B1 showed a two-fold reduc-
tion in KM with a two-fold increase in kcat, with the overall
efficiency of the enzyme remaining unchanged with
respect to F-dAdo. Unlike the wild-type PNP, enzymatic
activity of hDM-αH-C6.5 MH3B1 with respect to guanos-
ine was weak (data not shown). A cell based assay con-
firmed that the fusion protein converts F-dAdo to a
cytotoxic agent. First, a concentration of F-dAdo was
determined that was not toxic to cells, but if converted to
F-Ade, would inhibit cellular proliferation; this concentra-
tion was 1.5 μM for CT26 or CT26HER2/neu and 6 μM forPage 4 of 12
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mally when either 1.5 μM of F-dAdo or 0.2 μM of hDM-
αH-C6.5 MH3B1 was added (Fig. 2B), but when added
together, F-dAdo was converted to F-Ade by hDM and cell
proliferation was inhibited (Fig. 2B). In a similar experi-
ment using MCF7-HER2 cells, addition of 6 μM F-dAdo or
0.1 μM of hDM-αH-C6.5 MH3B1 did not affect cell pro-
liferation (Fig. 2C); however, addition of hDM-αH-C6.5
MH3B1 in the presence of 6 μM F-dAdo inhibited cell pro-
liferation in a dose dependent manner with half-maxi-
mum inhibition of proliferation at 0.6 nM, and complete
inhibition of cell proliferation at 2 nM (Fig. 2C). Since no
toxicity was seen with 6 μM of F-dAdo or 0.1 μM of hDM-
αH-C6.5 MH3B1 (Fig. 2C), the observed cytotoxicity
must be the result of the conversion of F-dAdo to F-Ade
through the enzymatic activity of hDM. In summary, F-
dAdo is toxic to cells only when cleaved to the cytotoxic
drug, F-Ade by hDM-αH-C6.5 MH3B1. Significantly, F-
Ade inhibits proliferation of a variety of cell types includ-
ing the murine colon carcinoma CT26 or CT26HER2/neu
and the human breast cancer line MCF7-HER2, as well as
melanoma tumor cell line, B16 and murine B-cell tumor
cells, 38C13 (data not shown).
Addition of hPNP-αH-C6.5 MH3B1 and F-dAdo to either
MCF7-HER2 or CT26-HER2/neu cells did not result in
cytotoxicity (Fig. 2D), consistent with the fact that the
wild type enzyme cannot use F-dAdo as substrate (Table
1). However, hPNP-αH-C6.5 MH3B1 is able to cleave its
natural substrate, guanosine, although with a KM of 59μM, a kcat of 60 s-1 and an overall efficiency of 1 × 106 M-
1s-1 (Table 2) that is 3 to 7-fold less than the reported val-
ues for the free enzyme [5,6].
Stability of hDM-αH-C6.5 MH3B1 at 37°C in the presence 
of serum
The stability of hDM-αH-C6.5 MH3B1 in serum at 37°C
was evaluated by its ability to cleave F-dAdo to F-Ade. It
was expected that different concentrations of F-Ade would
be produced depending on the activity of the added
enzyme. It had previously been determined that at a con-
centration of 0.001 μM, the activity of hDM-αH-C6.5
MH3B1 is limiting (Fig. 2C), and hence any partial or
complete loss in its activity would be measurable. There-
fore, 0.001 μM of hDM-αH-C6.5 MH3B1 was either
stored in PBS at 4°C or incubated with fetal bovine serum
at 37°C for various times, followed by immediate transfer
to 4°C until completion of the assay (~23 hours). Differ-
ent aliquots of the fusion protein were added to MCF-
7HER2 cells in the presence of 6 μM F-dAdo, and follow-
ing incubation for 72 hours at 37°C, cell proliferation was
determined by the MTS assay. As shown in Figure 3, incu-
bation of the fusion protein overnight at 4°C in the pres-
ence of serum resulted in loss of activity compared to the
enzyme that was incubated in PBS. When the fusion pro-
tein was incubated in serum at 37°C, a time dependent
loss in activity was observed. However, even after 23
hours at 37°C in the presence of serum, some enzyme
activity remained (Fig. 3). Consistent with these findings,
when a 10-fold higher concentration (0.01 μM) of fusion
protein was used, after 23 hours at 37°C sufficient
enzyme activity remained to cleave F-dAdo and result in
complete inhibition of cell proliferation (data not
shown).
hDM-αH-C6.5 MH3B1 binds to HER2/neu with high 
affinity and specificity
The specific interaction of hDM-αH-C6.5 MH3B1 with
ECDHER2 was demonstrated using three different
approaches. First, binding of hDM-αH-C6.5 MH3B1 to
ECDHER2 conjugated to Sepharose beads was used to
purify the fusion protein. Treatment with glycine pH 2.5
was required to elute the bound protein, consistent with a
strong interaction between hDM-αH-C6.5 MH3B1 and
ECDHER2. In a second approach, the interaction was eval-
Schematic presentation and purity ofhDM-αH-C6 MH3B1Figure 1
Schematic presentation and purity ofhDM-αH-C6 
MH3B1. (A), Schematic diagram of hDM-αH-C6 MH3B1. 
Each monomer of hDM is shown as filled oval. The αH linker, 
fused to the C-terminus of hDM is shown in black and C6 
MH3B1 is shown as hexagons. (B), SDS-PAGE analysis under 
non-reducing and reducing conditions of purified hDM-αH-
C6.5 MH3B1 visualized by Coomassie Blue staining. Lanes 1, 
4, 5, and 8, MW markers in kDa (Invitrogen); lanes 2 & 3, 
hDM-αH-C6.5 MH3B1 at 1 and 2 μg, respectively, not 
reduced; lane 6 & 7, hDM-αH-C6.5 MH3B1 at 1 and 2 μg, 
respectively, reduced. (C), Size exclusion chromatography of 
hDM-αH-C6.5 MH3B1 under non-reducing condition using a 
Sepharose-6 column. For comparison, molecular weight 
standards were analyzed under identical conditions.
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MH3B1 and ECDHER2 exist as a trimer (Fig. 1) and a mon-
omer respectively. To make the analysis of the binding
more straightforward, trimeric hDM-αH-C6.5 MH3B1
was immobilized on the sensor chip, so that the measured
binding should represent the interaction of a single bind-
ing site of hDM-αH-C6.5 MH3B1 with monomeric
ECDHER2. Different concentrations of ECDHER2 were
flowed for 750 seconds over immobilized hDM-αH-C6.5
MH3B1 at 30 μl/min (Fig. 4A), and binding was observed
as an increase in RUs. From these data, the binding affin-
ity of hDM-αH-C6.5 MH3B1 to ECDHER2 was calculated
using a 1:1 binding model to be 3.4 × 10-10 M, with a kon
of 1.7 × 104 M-1s-1 and a Koff of 5.8 × 10-6 s-1, values similar
to what had been observed with single chain C6.5 MH3B1
[7]. Incubation of ECDHER2 with hDM-αH-C6.5 MH3B1
prior to the injection prevented the binding of ECDHER2 to
immobilized hDM-αH-C6.5 MH3B1 (Fig. 4A, a-f). In a
third approach, the interaction of hDM-αH-C6.5 MH3B1
with ECDHER2 expressed on the cell surface was analyzed
by flow-cytometry. Biotinylated hDM-αH-C6.5 MH3B1








hPNP-αH-C6 MH3B1 nd nd Nd
hDM-αH-C6 MH3B1 264 ± 22 0.155 ± 0.017 568.2
nd: no activity detected
Enzymatic activity of hDM-αH-C6.5 MH3B1Figure 2
Enzymatic activity of hDM-αH-C6.5 MH3B1. (A), Lineweaver-Burk plot of enzyme activity of hDM-αH-C6.5 MH3B1 
with F-dAdo as substrate. Conversion of F-dAdo to F-Ade was followed spectrophotometrically in real time by the increase in 
absorbance at 280 nm. Concentration of F-dAdo is in μM and v is based on mili-units of absorbance/min. (B), Proliferation of 
CT26 and CT26HER2/neu cells and (C), MCF-7HER2 cells in the presence or absence of F-dAdo or hDM-αH-C6.5 MH3B1 
was determined in 72 hours by MTS. (D), 0.2 μM of hPNP-αH-C6.5 MH3B1 was incubated with CT26HER2/neu or MCF-7 
cells in the presence of 1.5 or 6 μM of F-dAdo respectively for 72 hours and cellular proliferation determined by MTS assay. 
Error bars for each graph represent standard deviation within each set of values.
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parental CT26 cells that lack expression of HER2/neu (Fig.
4B). Biotinylated hDM-αH-C6.5 MH3B1 also bound to
MCF-7HER2 cells (Fig. 4B). In summary, hDM-αH-C6.5
MH3B1 interacts specifically and with high affinity with
both soluble and cell-expressed ECDHER2.
hDM in hDM-αH-C6.5 MH3B1 can target cytotoxic 
activity to HER2/neu expressing cells
To determine if hDM-αH-C6.5 MH3B1 activity can be
specifically targeted to HER2/neu expressing cells, fusion
protein was incubated at room temperature for 45 min-
utes with CT26HER2/neu, the parental CT26 cells that lack
the expression of HER2/neu or MCF-7HER2. The
unbound protein was washed away, 1.5 μM or 6 μM of F-
dAdo added, and after 72 hours the amount of cell prolif-
eration was determined by MTS. hDM-αH-C6.5 MH3B1
was found to remain bound to HER2/neu expressing cells,
causing a dose dependent inhibition of cell proliferation
in the presence of F-dAdo as a consequence of its conver-
sion to F-Ade. No cytotoxicity was seen with CT26 cells
that did not express HER2/neu (Fig. 5A). For CT26HER2/
neu and MCF-7HER2 cells the IC50 for hDM-αH-C6.5
MH3B1 was 0.0196 μM and 0.0254 μM, respectively. In
summary, enzymatic activity of hDM-αH-C6.5 MH3B1
remains associated with HER2/neu expressing cells and
causes cleavage of F-dAdo to F-Ade resulting in dose
dependent inhibition of cell proliferation.
Conversion of F-dAdo to F-Ade by cell bound 
hDM-αH-C6.5 MH3B1 results in bystander activity
For ADEPT to be effective, the cytotoxic drug generated by
the activity of the cell associated enzyme should be cyto-
toxic to the neighboring cells that may lack the expression
of the tumor associated antigen. To investigate the
bystander effect of F-Ade generated by the enzymatic
activity of hDM-αH-C6.5 MH3B1, different ratios of
CT26HER2/neu and CT26 cells were mixed and seeded.
The next day, cells were incubated with 0.1 μM of hDM-
αH-C6.5 MH3B1 for 45 minutes, washed twice, and after
72 hours the level of inhibition of cell proliferation
caused by F-Ade that was generated by the enzymatic
activity of bound hDM-αH-C6.5 MH3B1 was determined
by MTS assay. Complete inhibition of cell proliferation
was achieved when up to 35% of the seeded cells were
comprised of CT26 (Fig. 5B). When 75% of the cells were
CT26, 50% inhibition of cell growth was observed (Fig.
5B). This result indicates that the F-Ade generated by the
enzymatic activity of hDM-αH-C6.5 MH3B1 bound to
CT26HER2/neu is not only toxic to HER2/neu expressing
cells, but also to the neighboring cells that lack the expres-
sion of tumor antigen.
F-Ade is toxic to rapidly, slowly and non-dividing cells
Since it has been shown that the non-dividing stromal
cells play a critical role in providing support for tumor
growth, and since tumors are composed of cells growing
at different rates, we examined the cytotoxic affect of F-
Ade on slowly-dividing or non-dividing cells. MCF-
7HER2 cells were grown overnight in growth medium that
contained 10% fetal bovine serum. The next day, cells
were washed and incubated for 72 hours in medium that
contained varying amounts of serum. MCF-7HER2 cells
divided even with serum levels as low as 0.25% and
ceased to divide, but remained viable only when no serum
was present (Fig. 5C). In the presence of different concen-








hPNP-αH-C6 MH3B1 59 ± 10 60 ± 13 1.02 × 104
Stability of hDM-αH-C6.5 MH3B1 at 37°C in the presence of serumFig re 3
Stability of hDM-αH-C6.5 MH3B1 at 37°C in the 
presence of serum. hDM-αH-C6.5 MH3B1 was either 
stored in PBS at 4°C or incubated for various times at 37°C 
in the presence of serum. After incubation at 37°C, fusion 
protein was stored at 4°C until the experiment was com-
pleted (~23 hours). hDM-αH-C6.5 MH3B1 was then added 
to MCF-7HER2 cells and its enzymatic stability was evaluated 
by its ability to convert F-dAdo to F-Ade resulting in inhibi-
tion of cellular proliferation. Data are shown as percent 
activity remaining of 0.001 μM of hDM-αH-C6.5 MH3B1 
incubated in serum at 37°C for various times relative to the 
activity of 0.001 μM of hDM-αH-C6.5 MH3B1 in PBS at 4°C. 
The error bars represent standard deviation within each set 
of values.
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spective of the rate of cell growth (Fig. 5D). This indicates
that F-Ade is toxic to the rapidly or slowly growing tumor
cells as well as to the non-dividing neighboring cells that
may sustain tumor growth.
Novel MHCII binding peptides present in hDM-αH-C6 
MH3B1
B cells are activated to develop into antibody producing
plasma cells when their B cell receptor interacts with non-
self epitopes on soluble proteins and when they receive a
signal from TH cells. It seems likely that hDM-αH-C6
MH3B1 will exhibit minimal reactivity with the B cell
receptor because the two introduced mutations are buried
within the purine binding pocket of hDM and the struc-
ture of hDM is extremely similar to the structure of wild
type enzyme [13]. A recently developed evaluation tool
which identifies peptides that might bind to MHCII mol-
ecules [16] was used to identify potential MHCII binding
peptides present in hDM-αH-C6 MH3B1. After the pep-
tides common between hDM and hPNP were eliminated,
10 and 1 new possible binders that were generated as a
result of Glu201Gln and Asn243Asp mutations respec-
tively were identified. Although, hDM and C6 MH3B1 are
both human derived proteins, novel MHCII binding pep-
tides may result from their fusion. To address this possi-
bility, we also evaluated a 40 amino acid long peptide that
included 14 amino acids from the C-terminus of hDM,
the complete sequence of the α-helical linker and a 14
amino acids stretch of the N-terminus of C6 MH3B1 for
Binding of hDM-αH-C6.5 MH3B1 to ECDHER2F gure 4
Binding of hDM-αH-C6.5 MH3B1 to ECDHER2. (A), Interaction of ECDHER2 with hDM-αH-C6.5 MH3B1 immobilized on 
the surface of a SPR chip. ECDHER2 at concentrations of a) 100 nM in duplicate b) 50 nM in duplicate c) 40 nM d) 20 nM in dupli-
cate or e) 10 nM was flowed across the sensor chip at 30 μl/min for 750 second. f) Binding of 100 nM ECDHER2 to immobilized 
hDM-αH-C6.5 MH3B1 after incubation with 1 μM hDM-αH-C6.5 MH3B1. (B), Binding of biotinylated hDM-αH-C6.5 MH3B1 
to ECDHER2 expressed on the cell surface. Bound protein was detected using Streptavidin-PE. Left panel shows binding of 0.5 
μg of biotinylated hDM-αH-C6.5 MH3B1 to CT26HER2/neu and not to the parental cells that lack HER2/neu expression. Right 
panel shows binding of 0.1 μg (heavy green), or 0.5 μg of biotinylated hDM-αH-C6.5 MH3B1 (thin blue) or Streptavidin-PE 
(heavy black) to MCF-7HER2 cells. Filled are unstained cells.
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MHCII binding peptides for all human MHCII alleles
were identified suggesting that minimal immunogenicity
should result from the fusion of hDM to C6 MH3B1.
Therefore, the probability of hDM-αH-C6 MH3B1 induc-
ing a robust immune response in human should be min-
imal.
Discussion
In order to develop a clinically relevant non-immuno-
genic therapeutic approach to ADEPT, we fused a mutant
human enzyme to a human scFv specific for the HER2/neu
tumor antigen. ADEPT requires both an active enzyme
and the ability to target that enzyme to the tumor. Here we
show that fusion of the mutant human PNP to the anti-
HER2/neu scFv via an α-helical linker (hDM-αH-C6.5
MH3B1) results in an active protein that can be targeted
to tumor cells, where it can cleave a relatively non-toxic
prodrug to a cytotoxic drug, resulting in the inhibition of
tumor cell proliferation.
Previously it was shown that fusion of a 1.5 kDa short
anti-HER2/neu peptide (AHNP) to the C-terminus of
hDM did not result in loss of enzyme activity [5]. We have
hDM-αH-C6.5 MH3B1 specifically associates with HER2/neu expressing cells and causes cytotoxicty in the presence of F-dAdo irrespective of expression of tumor antigen or cell growth rateFigur  5
hDM-αH-C6.5 MH3B1 specifically associates with HER2/neu expressing cells and causes cytotoxicty in the 
presence of F-dAdo irrespective of expression of tumor antigen or cell growth rate. (A), hDM-αH-C6.5 MH3B1 
associates with HER2/neu expressing cells resulting in concentration dependent cytotoxicity upon addition of 1.5 or 6 μM F-
dAdo to CT26HER2/neu or MCF-7HER2 cells respectively. Different concentrations of hDM-αH-C6.5 MH3B1 were incubated 
with cells, unbound enzyme washed away, F-dAdo added and 72 hours later cellular proliferation was determined by MTS 
assay. (B), CT26HER2/neu and CT26 cells were seeded at different ratios and grown overnight. hDM-αH-C6.5 MH3B1 was 
incubated with cells for 45 minutes, and washed away. Cells were then grown in the presence of 1.5 μM F-dAdo for 72 hours 
and cell proliferation determined by MTS assay. (C), MCF-7HER2 cells were grown overnight (O/N) in the presence of 10% 
serum, washed and growth continued for 72 hours in the presence of varying amounts of serum. The column labeled overnight 
(O/N) represents the number of cells prior to switching to different amounts of serum. The number of cells was determined 
by visually counting the cells. (D), Viability of MCF-7HER2 cells in the presence of different amounts of fetal bovine serum and 
1.5 μM F-Ade was determined after 72 hours of incubation by MTS assay. Error bars for each graph represent standard devia-
tion within each set of values.
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AHNP with the much larger (~50 kDa) scFv also did not
significantly affect the activity of hDM (Table 1). In this
fusion protein, a rigid α-helical linker was used to join the
two domains. The spacing provided by the inflexible
linker may minimize steric hinderace that could adversely
influence the activity of either hDM or C6.5 MH3B1.
Moreover, the C-terminus of the enzyme is extended away
from the enzyme active site; therefore, fusion of a target-
ing component to the C-terminus of hDM should have a
minimal affect on substrate binding and catalysis. Since
hDM remains active after fusion to C6.5 MH3B1, it is rea-
sonable to expect that following fusion of other scFvs with
different specificities to hDM, the enzyme will remain
active and capable of being targeted to other tumors.
Therefore, the use of hDM is not restricted to HER/neu
expressing tumors, but should be useful for ADEPT ther-
apy of a wide variety of cancers.
Fusion of hDM to the single chain C6.5 MH3B1 resulted
in specific association of the enzyme activity with the
HER2/neu expressing cells (Fig. 5A). C6.5 MH3B1 was
chosen to target hDM to the tumor site based on its spe-
cificity, high affinity and slow dissociation rate from the
HER2/neu tumor antigen [7]. SPR analysis of the binding
affinity of hDM-αH-C6.5 MH3B1 to ECDHER2 showed a
strong binding affinity of 3.4 × 10-10 M, approximately
three fold less strong than that of the single chain C6.5
MH3B1 [7]. The trimeric structure of hDM-αH-C6.5
MH3B1 should further increase its binding to cell associ-
ated HER2/neu. The high affinity should ensure that
hDM-αH-C6.5 MH3B1 effectively targets the tumor and
persists at the tumor site long enough to allow the system-
ically administered F-dAdo to reach the tumor and be
cleaved to F-Ade [5,7,17,18]. It has been suggested that
high affinity scFvs would mainly be retained in the
perivascular regions of the tumor where the first tumor
antigen is encountered [19], preventing tumor penetra-
tion. While this might weaken the clinical applicability of
some therapeutic scFvs, it should not be an issue for
ADEPT. In fact, retention of hDM-αH-C6.5 MH3B1 on
the cell surface in the tumor microenvironment for an
extended period of time should make the enzyme readily
accessible for cleaving the prodrug to a cytotoxic drug.
Properties of hDM-αH-C6.5 MH3B1, such as thermal sta-
bility and resistance to proteolysis contribute to its effec-
tiveness in vitro and in vivo. When hDM-αH-C6.5 MH3B1
was incubated with serum at 37°C only 50% of enzyme
activity was recovered after 30 minutes (Fig. 3). Longer
incubation resulted in a further rapid loss of activity so
that after 3 hours only about 30% of the activity
remained. However, further incubations for 21 hours
resulted in little further decrease in activity (Fig. 3). Incu-
bation with serum over night at 4°C resulted in a 20%
loss of activity (Fig. 3). The observed loss of enzyme activ-
ity in the presence of serum is most probably due to deg-
radation of the protein by the serum proteases and the
small additional decrease in enzyme activity following 3
hours of incubation may indicate that the serum proteases
themselves become inactivated upon incubation and lose
activity by 3 hours. Alternatively, there may exist different
conformers of hDM-αH-C6.5 MH3B1 that exhibit differ-
ent stabilities in serum.
The use of hDM with F-dAdo constitutes a novel and spe-
cific enzyme-prodrug combination. Addition of hDM-
αH-C6.5 MH3B1 alone, F-dAdo alone or hPNP-αH-C6.5
MH3B1 with F-dAdo, did not affect cell proliferation. This
is particularly important since hPNP is a ubiquitous
enzyme present at micromolar concentrations in blood
cells [12]. Therefore, lack of activity of hPNP-αH-C6.5
MH3B1 with F-dAdo should reduce toxicity concerns in
vivo. However, when hDM-αH-C6.5 MH3B1 was added
to cells in the presence of F-dAdo, the cytotoxic F-Ade gen-
erated due to enzymatic activity of hDM-αH-C6.5 MH3B1
resulted in a dose-dependent inhibition of cell prolifera-
tion (Fig. 2C). Our in vitro studies have shown that F-dAdo
conversion to F-Ade occurs by hDM that is targeted to
tumor cells through specific interaction of C6.5 MH3B1
with cell expressed HER2/neu. However, the generated F-
Ade is toxic to all tumor cells regardless of their expression
of tumor antigen. When 65% of cells express HER2/neu,
enzymatic activity of hDM-αH-C6.5 MH3B1 that is
bound on their cell surface, resulted in generation of suf-
ficient F-Ade to inhibit proliferation of all the tumor cells,
regardless of their expression of HER2/neu (Fig. 5B).
While the mechanism of F-Ade passage from cell to cell is
not exactly known, it has been shown to be independent
of gap junctions and does not require cell-cell contact
[20,21]. In addition to being able to kill the rapidly divid-
ing tumor cells, F-Ade can also cross the cell membrane of
the slowly-dividing or even non-dividing neighboring
cells and cause cytotoxicity (Fig. 5D). This is especially
important since tumors are heterogeneous and are com-
posed of cells with different growth rates. Moreover,
neighboring stromal cells that do not divide play an
important role in supporting tumor growth. Therefore, F-
Ade that inhibits DNA, RNA as well as protein synthesis
[22], can effectively cause growth arrest in all cell types
that contribute to tumor survival, while exerting minimal
toxicity to the distal healthy cells due to its expected short
half-life of only 5 hours in vivo [22].
An important consideration is whether hDM-αH-C6
MH3B1 will induce an immune response in humans.
Generation of antibodies against the bacterial enzyme
and the murine targeting component in patients receiving
ADEPT has to date prevented further treatment [2,23].
Antibodies are produced against foreign substances byPage 10 of 12
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epitopes and received signals from an activated TH cell. In
hDM, the two introduced mutations, E201Q:N243D are
buried within the enzyme; hence, they are not directly
accessible to bind the B cell receptor. Moreover, we have
shown that the overall structure of hDM with F-dAdo is
very similar to that of hPNP complexed with its natural
substrate, guanosine. Although, the presence of neo-
epitopes cannot be dismissed, it is anticipated that the
mutant enzyme should have minimal reactivity with the B
cell receptor. Additionally, fusion is achieved by using a
rigid αH linker, whose rigidity should make the whole
molecule less flexible and therefore less immunogenic
[24,25].
In contrast to the B cell receptor, the T cell receptor recog-
nizes non-self epitopes by recognizing protein-derived
peptide fragments bound to MHC molecules. Therefore,
T-cells can react to foreign epitopes that are buried within
a protein. To be recognized by T cells, the peptides must
first bind to MHC molecules expressed on the surface of
antigen presenting cells. However, binding of a peptide to
MHCII does not necessarily result in TH cell activation,
and only 9.4% of the predicted binders have been found
to actually activate T cells [16]. Given that only 11 new
possible binders are predicted to result from the intro-
duced mutations, the likelihood of hDM activating TH
cells is small. Therefore, we propose that hDM should be
far less immunogenic than the currently used bacterial
enzymes.
Conclusion
In this study, we have demonstrated the feasibility of
ADEPT in which both the enzyme and the targeting moi-
ety are of human origin. Our study has shown that hDM,
a version of human PNP with only two amino acid substi-
tutions, can be fused to a targeting component comprised
of a human-derived scFv without loss of activity. Moreo-
ver, we have shown that the drug generated by the enzy-
matic activity of hDM causes tumor cell death regardless
of their expression of tumor associated antigen or growth
rate. We anticipate that effective tumor cell targeting of
hDM will result in localized tumor cytotoxicity in vivo.
Our findings should provide important insights into
approaches for the development of superior all human
ADEPT.
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